United Therapeutics (UTHR) Long-Term Debt Repayments (2015 - 2016)

United Therapeutics' (UTHR) quarterly Long-Term Debt Repayments came in at $900000.0 in Q3 2016, down 67.86% year-on-year from $2.8 million in Q4 2015, and down 88.46% quarter-over-quarter from $7.8 million in Q2 2016.

United Therapeutics (UTHR) Long-Term Debt Repayments (2015 - 2016) Analysis & Trends

United Therapeutics has disclosed Long-Term Debt Repayments across 2 years of filings, most recently posting $900000.0 for Q3 2016.

  • Long-Term Debt Repayments for Q3 2016 came in at $900000.0, down 67.86% year-over-year; the trailing twelve-month figure through Dec 2016 was $8.8 million (down 93.39% YoY), and the FY2016 annual result was $8.8 million, down 93.39% from the prior year.
  • Long-Term Debt Repayments came in at $900000.0 for Q3 2016 at United Therapeutics, down from $7.8 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $90.3 million in Q2 2015 to a low of $100000.0 in Q1 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 23.00 Mn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn -
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn -
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn -
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn -
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 216,000.00
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn -
10 Liquidia 5.63 Bn 5.40 Bn 121.79 Mn 19.97 Mn

Historic Data

Download Data
DateValue
Sep 30, 2016 900,000.00
Sep 30, 2016 900,000.00
Jun 30, 2016 7.80 Mn
Jun 30, 2016 7.80 Mn
Mar 31, 2016 100,000.00
Mar 31, 2016 100,000.00
Dec 31, 2015 26.10 Mn
Dec 31, 2015 26.10 Mn
Sep 30, 2015 2.80 Mn
Sep 30, 2015 2.80 Mn
Jun 30, 2015 90.30 Mn
Jun 30, 2015 90.30 Mn
Mar 31, 2015 14.00 Mn
Mar 31, 2015 14.00 Mn